Breakthrough Therapy status for rilzabrutinib in wAIHA addressed the lack of approved treatments for this rare and life-threatening condition.

Anemia is the most prevalent blood condition in the U.S. Annually, the condition accounts for 2.8 million visits to physician offices with anemia as the primary diagnosis, according the Centers for ...

Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic ...

Comorbidities and advanced CKD were prevalent among the approximately 275,000 patients with anemia of CKD from the international DISCOVER CKD cohort. Patients with anemia of chronic kidney disease ...

In the prospective CKD-DOPPS study, only 40% for patients with hemoglobin less than 10 g/dL initiated anemia medication. Only a subset of patients with nondialysis-dependent chronic kidney disease ...

Clinical stage generative artificial intelligence (AI)-driven biotechnology company InSilico Medicine ("InSilico"), today announced that the Journal of Medicinal Chemistry, an ACS Publications journal ...

In the CREDENCE trial, patients receiving canagliflozin had reduced risks of initiating iron therapy and erythropoiesis-stimulating agents compared with patients receiving placebo. In addition to its ...

The most prevalent cause of anaemia during pregnancy is iron deficiency anaemia (IDA), which is a microcytic anaemia characterised by impaired red blood cell formation. IDA is linked to ...

Please provide your email address to receive an email when new articles are posted on . In this video, Jay B. Wish, MD, professor of clinical medicine at Indiana University School of Medicine, ...

LAS VEGAS — Treating non-anemic iron deficiency (NAID) with iron and vitamin C raised third-trimester hemoglobin levels and ...